Though the number of merger and acquisition deals in the first quarter of 2021 fell below historical averages, the size of the deals was far bigger than the same period last year, a new report from Kaufman Hall shows. The total transacted revenue was $8.8… Read More »Report: Fewer health system M&A deals in Q1 2021 offset by larger transactions
Peter Meath, J.P. Morgan Commercial Banking’s Co-Head of Healthcare and Life Sciences, applies lessons from 2020’s remarkable second half and shares insights on what to expect in 2021.
Merck agreed to pay $215 million up front to acquire Alydia Health, a startup that has commercialized a medical device that controls bleeding during childbirth. That product will join the portfolio of Merck spinout company Organon.
Grifols’s acquisition of GigaGen comes as the startup’s Covid-19 antibody drug is set to start Phase 1 testing. Barcelona-based Grifols says GigaGen’s technology could also help it expand to engineered antibody therapies.
Takeda Pharmaceutical and Maverick Therapeutics have been R&D partners since 2017. In buying out its partner, Takeda acquires technology and drug candidates that could offer advantages compared to CAR-T therapies, including the potential to treat solid tumors.
As a result of rapid consolidation, the 10 biggest health systems controlled 24% of market share based on patient revenue by 2018. The trend is expected to continue through the next decade, with health systems facing growing financial pressures and an increase in demand for… Read More »Financial strain, new modes of care delivery to drive provider consolidation through 2030